Baritosis

Summary

Baritosis (MONDO:0001001) is a disease. A subtype of pneumoconiosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	baritosis
Mondo ID	MONDO:0001001
MeSH	C537080
DOID	DOID:10321
NCIT	C34410
SNOMED CT	50076003
UMLS	C0340177
MedGen	87399
GARD	0008371
Is cancer (heuristic)	no

Also known as: deposition of barium in the lungs · inhalation of barytes

Disease family

This is a subtype of pneumoconiosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › interstitial lung disease › pneumoconiosis › baritosis

Related subtypes (13): mixed mineral dust pneumoconiosis, pneumoconiosis due to talc, slate pneumoconiosis, Caplan syndrome, silicosis, anthracosilicosis, anthracosis, byssinosis, pulmonary hemosiderosis, chronic beryllium disease, asbestosis, mixed dust pneumoconiosis, graphite pneumoconiosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.